Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Capricor Therapeutics, Inc.    CAPR

CAPRICOR THERAPEUTICS, INC.

(CAPR)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Capricor Therapeutics : SEC Filing - 8-K

share with twitter share with LinkedIn share with facebook
02/18/2020 | 06:05am EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

February 12, 2020

CAPRICOR THERAPEUTICS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware 001-34058 88-0363465
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

8840 Wilshire Blvd., 2nd Floor, Beverly Hills, CA

(Address of principal executive offices)

90211

(Zip Code)

(310) 358-3200

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 12, 2020, pursuant to the authority granted to it under the 2012 Restated Equity Incentive Plan (the '2012 Plan') and the 2012 Non-Employee Director Stock Option Plan (the '2012 Director Plan'), the board of directors of the Company approved a program under which outstanding options and other awards granted under the 2012 Plan and the 2012 Director Plan to employees, officers and directors of the Company, and designated service providers shall be repriced to their then current fair market value. The Company's Chief Executive Officer, Linda Marban, the Company's Chief Financial Officer, Anthony Bergmann, and the Company's Executive Vice President and General Counsel, Karen Krasney, are all eligible to participate in the repricing program with respect to their outstanding option awards.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CAPRICOR THERAPEUTICS, INC.
Date: February 14, 2020 By: /s/ Linda Marbán, Ph.D.
Linda Marbán, Ph.D.
Chief Executive Officer

Disclaimer

Capricor Therapeutics Inc. published this content on 18 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 February 2020 11:04:10 UTC

share with twitter share with LinkedIn share with facebook
Latest news on CAPRICOR THERAPEUTICS, INC
07/30Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Re..
GL
06/09CAPRICOR THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holder..
AQ
06/04Capricor to Participate in BIO Digital International Convention
GL
05/28CAPRICOR THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and..
AQ
05/26Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series o..
GL
05/15CAPRICOR THERAPEUTICS : Management's Discussion and Analysis of Financial Condit..
AQ
05/15CAPRICOR THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and..
AQ
05/14CAPRICOR : 1Q Earnings Snapshot
AQ
05/14CAPRICOR THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fin..
AQ
05/14Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provid..
GL
More news
Financials (USD)
Sales 2020 0,19 M - -
Net income 2020 -9,24 M - -
Net Debt 2020 - - -
P/E ratio 2020 -8,12x
Yield 2020 -
Capitalization 114 M 114 M -
Capi. / Sales 2020 610x
Capi. / Sales 2021 252x
Nbr of Employees 16
Free-Float 96,4%
Chart CAPRICOR THERAPEUTICS, INC.
Duration : Period :
Capricor Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CAPRICOR THERAPEUTICS, INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 10,50 $
Last Close Price 7,96 $
Spread / Highest target 50,8%
Spread / Average Target 31,9%
Spread / Lowest Target 13,1%
EPS Revisions
Managers
NameTitle
Linda Marbán President, Chief Executive Officer & Director
Frank Litvack Executive Chairman
Anthony Bergmann Chief Financial Officer
Siegfried S. Rogy Vice President-Clinical Operations
Louis Manzo Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CAPRICOR THERAPEUTICS, INC.521.88%114
GILEAD SCIENCES, INC.7.02%87 217
VERTEX PHARMACEUTICALS24.23%70 523
REGENERON PHARMACEUTICALS68.34%64 189
WUXI APPTEC CO., LTD.71.73%37 176
GENMAB A/S45.73%22 395